Lake Street analyst Frank Takkinen lowered the firm’s price target on Pulmonx (LUNG) to $8 from $12 and keeps a Buy rating on the shares. Despite a “strong” Q2, Pulmonx guided 2025 revenue growth down to 7%-10% from the previous 15%-17% growth expectation, notes the analyst, who calls the guide down “a prudent reset.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUNG: